Gujarat Themis Biosyn Ltd. Share Price

GUJARAT THEMIS COMPLETES RS 1,220-CRORE FUNDING

Gujarat Themis Biosyn Limited announced on Friday that it has completed the acquisition of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) for ¥21.5 billion, equivalent to approximately ₹1,300 crore. The transaction gives the Indian fermentation-focused pharmaceutical company access to new technologies, regulated manufacturing facilities and established relationships with global pharmaceutical companies. The acquisition, initially announced on May 22, was completed through GTBL’s wholly owned Japanese subsidiary, Themis Biosyn Japan Limited (TBJ), after all required regulatory approvals were secured and other closing conditions were fulfilled. To finance the transaction, GTBL invested ₹475 crore as equity capital and provided a ₹745-crore loan to TBJ. The company has also entered into a loan agreement with TBJ for an additional facility of up to ₹800 crore. Avendus Capital arranged the entire acquisition financing through a combination of onshore and offshore debt. Avendus Structured Credit Fund III served as the lead investor for the onshore debt component. The acquisition combines GTBL’s Indian fermentation capabilities and manufacturing scale with MBJ’s more than 60 years of pharmaceutical research, development and manufacturing experience. MBJ also brings long-standing relationships with global pharmaceutical companies. GTBL expects to use its lower-cost Indian manufacturing base alongside MBJ’s technology and customer network to improve cost competitiveness and potentially expand margins on higher-value products. The company also expects the acquisition to be accretive to earnings per share.

See More

India’s Biopharma Push Could Create the Next Wave of Healthcare Growth

India is rapidly strengthening its position in the global biopharmaceutical industry through increased focus on innovation, manufacturing, clinical research, and regulatory development. At the 2nd Pharma Summit & Awards 2026, policymakers highlighted the growing importance of biopharmaceuticals in the future of healthcare and outlined the vision of the Biopharma SHAKTI initiative, which aims to launch 100 biologics by 2047. With biologics expected to account for nearly 40% of global prescription drugs by 2031, India is working to expand its capabilities in advanced biologics while continuing its leadership in affordable generic medicines. Government-backed initiatives such as the PRIP Scheme, National Biopharma Mission, and BIRAC programs including BIG, SBIRI, and BIPP are supporting research, innovation, manufacturing, startups, and the development of next-generation therapies. The broader objective is to strengthen clinical research infrastructure, build a skilled talent pool, improve supply chain resilience, accelerate drug discovery, and enhance India's competitiveness across the global biopharmaceutical value chain. This long-term policy focus reflects India's ambition to emerge as a major global hub for biologics, advanced therapies, and pharmaceutical innovation while supporting the vision of a developed and healthier nation by 2047. Key beneficiaries:

, , , and are likely to be among the strongest long-term beneficiaries if India successfully scales biologics manufacturing, biotech innovation, and CDMO services over the coming decades. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.

See More

Why Gujarat Themis Biosyn Rose 4% What a ₹1,300 Crore Japanese Acquisition Tells Investors

Gujarat Themis Biosyn shares rose 4% to ₹383.65 after announcing the acquisition of 100% stake in MicroBiopharm Japan a Japanese pharma and specialty chemicals company with over six decades of fermentation expertise for ₹1,300 crore (JPY 21.5 billion).The deal is expected to close in Q2 FY27 subject to regulatory approvals. MicroBiopharm Japan is a Japanese company with 60+ years of expertise in: Fermentation technology, Microbial based research and development ,Manufacturing of pharmaceuticals and specialty chemicals This is not a random acquisition it is a strategic purchase of deep scientific expertise that Gujarat Themis Biosyn cannot build overnight on its own. Japan a premium market : Japanese pharma standards are among the strictest globally. A company approved and operating in Japan automatically gains credibility in other regulated markets like the US and Europe. Specialty chemicals upside MicroBiopharm's specialty chemicals business adds a completely new revenue stream beyond pharmaceuticals diversifying Gujarat Themis Biosyn's income sources. The ₹1,300 crore acquisition will be financed through a combination of debt and equity. The deal will be executed through a Special Purpose Vehicle SPV incorporated in Japan. An SPV is a separate legal entity created specifically to complete this acquisition keeping the parent company's balance sheet protected during the transaction

Gujarat Themis Biosyn's ₹1,300 crore Japanese acquisition taught me that buying deep technical expertise through cross-border deals can instantly accelerate growth just as Sun Pharma and Divi's Labs did through strategic investments making it essential to evaluate what is being acquired and how it is financed before concluding any acquisition creates value for shareholders.

See More

Gujarat Themis Biosyn Makes ₹1,300 Crore Global Bet to Strengthen Biotech and CDMO Capabilities

Gujarat Themis Biosyn Ltd (

) the has announced a major international expansion move by signing a definitive agreement to acquire 100% equity of Japan-based MicroBiopharm Japan Co., Ltd. (MBJ) through its wholly owned subsidiary, Themis Biosyn Japan Ltd. The acquisition, valued at JPY 21.5 billion (approximately ₹1,300 crore), will be funded through a combination of debt and equity and is expected to be completed in Q2 FY27, subject to regulatory approvals and customary closing conditions. MBJ specializes in research, development and manufacturing of APIs, intermediates and contract development and manufacturing (CDMO) services, with expertise in microbial fermentation, biotechnology-based manufacturing, oncology APIs, plasmid DNA production, ADC conjugation and enzyme-based bioconversion. The acquisition marks a strategic shift for GTBL from a fermentation-focused intermediates business to a technology-driven CDMO platform with advanced biotechnology capabilities. MBJ is estimated to generate revenue of JPY 9.5 billion (around ₹570 crore) in FY26, while its revenue stood at approximately ₹470 crore in FY23, ₹580 crore in FY24 and ₹560 crore in FY25. The transaction is not a related-party deal, and the promoter group has no interest in the acquired entity. This acquisition highlights GTBL’s ambition to strengthen its global presence and participate in the growing opportunities across biotechnology, precision fermentation and next-generation pharmaceutical manufacturing. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.

See More

Gujarat Themis Biosyn Ltd (GUJTHEM

Strengths Niche Pharma Manufacturer: Focused on APIs and pharmaceutical intermediates. Strategic Location: Manufacturing facility in Gujarat, a major pharma hub. Regulatory Approvals: Compliance with domestic and international quality standards. Cost Efficiency: Lower manufacturing costs due to scale and process optimization. Parent Support: Backed by Themis Medicare group. Weaknesses Limited Product Portfolio: Dependence on a small number of products. Revenue Volatility: Earnings fluctuate due to API pricing cycles. Customer Concentration: Limited large buyers increase dependency risk. Low Market Visibility: Relatively low analyst coverage and liquidity. Opportunities Rising API Demand: Increasing focus on self-reliance in pharma manufacturing. Import Substitution: Government push to reduce dependency on China. Capacity Expansion: Scope to add new molecules and intermediates. Export Growth: Opportunity to enter regulated and semi-regulated markets. Pharma R&D Support: Policy incentives for bulk drug manufacturers. Threats Pricing Pressure: Intense competition from Chinese API manufacturers. Regulatory Risks: Changes in environmental and pharma compliance norms. Raw Material Volatility: Fluctuations in key input prices. Currency Risk: Forex fluctuations impacting export revenues. Environmental Scrutiny: Stricter pollution norms affecting operations. Disclaimer Disclaimer: This content is shared only for educational and informational purposes and should not be considered as investment advice or a recommendation to buy, sell, or hold any security. Stock market investments are subject to market risks. Please consult a SEBI-registered investment advisor before making any investment decisions. Registration Number: INH000013174

See More